(Boursier.com) — Nanobiotix a French biotechnology company in advanced clinical development, pioneering physics-based approaches to expand treatment options for cancer patients, today announced that it has completed the dose escalation portion of the Phase 1 study evaluating NBTXR3, potential first-in-class radioenhancer, in patients with recurrent, inoperable non-small cell lung cancer (NSCLC) who have previously been treated with definitive radiotherapy and are likely to be reirradiated.
The Phase 1 study (study 2020-0123) is being conducted by the University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing strategic collaboration with Nanobiotix.
“NBTXR3 is designed as an innovative product candidate with the potential to improve treatment outcomes for cancer patients in any setting where radiotherapy is part of the treatment regimen. While these patients suffer from different types of cancer and are each facing unique challenges, they share an urgent need for therapeutic innovations with the potential to make a difference,” said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. “We believe that the feasibility of the injection and the favorable safety profile we observed during the dose escalation portion of this Phase 1 lung cancer study could pave the way for additional clinical development of NBTXR3 for patients with recurrent, inoperable lung cancer susceptible to re-irradiation.”
This completed part of the dose escalation of study 2020 0123 made it possible to determine the recommended dose for Phase 2 (RP2D) after determining the feasibility of the injection and observing a favorable safety profile. The expansion portion of the study, evaluating additional safety signals and initial efficacy signals, is ongoing.
©2024 Boursier.com